Cancer News

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (11/06/2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle …

Continue reading "FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma"

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (08/09/2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. The Breakthrough Therapy Designation …

Continue reading "Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma"

CAR Therapy Effective in Advanced Lymphoma (06/20/2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types … Continue reading "CAR Therapy Effective in Advanced Lymphoma"